ArticleAdvances in therapy2020
Dysfunctional Coagulation in COVID-19: From Cell to Bedside.
Article in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Pooled it
- Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss.Journal of clinical medicine · 2025 · on this mapReview
- Bridging the gap between CVD and COVID-19: the oxidized LDL hypothesis.Frontiers in medicine · 2025Article
- The Role of Cardiac PET in Diagnosis and Prognosis of Ischemic Heart Disease: Optimal Modality Across Different Patient Populations.Current atherosclerosis reports · 2023Review
- Melatonin effect on platelets and coagulation: Implications for a prophylactic indication in COVID-19.Life sciences · 2022Review
- Renal, cardiac, neurological, cutaneous and coagulopathic long-term manifestations of COVID-19 after recovery; A review.Epidemiology and infection · 2022Review
- Memory impairment and concentration problems in COVID-19 survivors 8 weeks after non-ICU hospitalization: A retrospective cohort study.Journal of medical virology · 2022Article
- Immune system changes in those with hypertension when infected with SARS-CoV-2.Cellular immunology · 2022Review
- Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection?Biochimica et biophysica acta. Molecular and cell biology of lipids · 2022Review
- Role of LL-37 in thrombotic complications in patients with COVID-19.Cellular and molecular life sciences : CMLS · 2022Article
- Sequence complementarity between human noncoding RNAs and SARS-CoV-2 genes: What are the implications for human health?Biochimica et biophysica acta. Molecular basis of disease · 2022Article
- Endothelial dysfunction and COVID-19 (Review).Biomedical reports · 2021Review
- The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism.Expert opinion on drug safety · 2021Review
- Von Willebrand factor: A key glycoprotein involved in thrombo-inflammatory complications of COVID-19.Chemico-biological interactions · 2021Review
- Neurological manifestations of COVID-19: A comprehensive literature review and discussion of mechanisms.Journal of neuroimmunology · 2021Review
- Ambient air pollution and low temperature associated with case fatality of COVID-19: A nationwide retrospective cohort study in China.Innovation (Cambridge (Mass.)) · 2021Article
- Altered platelet and coagulation function in moderate-to-severe COVID-19.Scientific reports · 2021Article
- Nervous System Involvement in COVID-19: a Review of the Current Knowledge.Molecular neurobiology · 2021Review
- Article
- Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics.Trends in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which can induce multisystem disease. Human angiotensin-converting enzyme 2 (ACE2) widely expressing in arterial and venous endothelial cells and arterial smooth muscle cells has been identified as a functional receptor for SARS-CoV-2. Dysfunction of ACE2 leads to abnormal activation of the renin-angiotensin system and a systemic endotheliitis that may relate to abnormal coagulation and sepsis. Meanwhile, innate immune response and inflammation activation participate in dysfunctional coagulation. Previous research indicated that dysfunctional coagulation was one of the important risk factors accountable for a high risk of severe disease and death in patients with COVID-19. Understanding the possible mechanisms of dysfunctional coagulation and appropriate anticoagulation therapeutic strategies are important to prevent disease deterioration and reduce fatality rates during the ongoing COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.